Member Info for Saxondale

my mistake - everythings showing up as double today.
Only the one 5k

Yes , and hes just had another 5000 at same price .

Someone is keen .
Nas is up a smidge , but we've never really worked out who Mr 5000 is .

Could have been the likes of Timo or someone all along .

Either way , its nice :-)

Shoved another pile in here this morning . That's about me done now .
17.5p ??
I'm lucky that i had some dry powder to take advantage .
Plenty if not most of my shares are down at the moment , but this is the one I feel most confident in adding to .

Another good interview .
Patterson Absolutely Elephant country .
Under Cover - cover is your friend . Modern techniques allowing them to reach these under explored zones .
Even another 1/4 Havieron find would be massive for GGP .

This is what excites me .
Investment is safe and sound with Havieron.
But to discover something else in the Patterson - now thats an extra jackpot .

Nice rumtastic appointment :-)

Yep shes holding steady . Even in a rocky market worldwide , she creaked over £4 for both bid and ask today .

Most if not all investors feel some value is going to be added to this company very soon .

Unlike some pharmas who have just started a trial , and its generally taken that there will be no outcome for so many months , we are in that end of P2 area , when anything could drop anytime .

And overdue a Matins update , and promised more data anyway in Q3 .

And lots going on in all other areas , be it Traumakine , Interferon manufacture , Patents , Grant applications , Boston etc .
Plus we should be getting some update on their progress with Heamatokine . Still preclinical , but no doubt they are making progress .

Added again today . Just a few grand , but I see this as a nice little nest egg . The longer the wait , the bigger the egg .

Nope , if anything make inhalers and nebulisers more widely accepted .
And freeze drying , including with IFN Beta1-a , also makes distribution , storage , and use in high temps possible .

Came across this article written about the Gold Standard etc , and views on returning to it .
https://qz.com/1646318/why-trump-and-judy-shelton-want-the-us-back-on-the-gold-standard/

The interesting slant is that it was written in July 2019 , when the author had no idea of what was around the corner .

Just had a re-read of last July's BBC breaking news about SNG001 , reported by BBC Chief Environment correspondent Justin Rowlatt.
https://www.bbc.co.uk/news/health-53467022
What an optimistic piece that was - with quotes such as :
Mr Marsden said the company will be presenting its findings to medical regulators around the world in the next couple of days to see what further information they require in order to approve the treatment.
That process could take months, although the British government, like many others, has said it will work as fast as possible to get promising coronavirus treatments approved.
It is possible it could be given emergency approval, as the anti-viral drug remdesivir was in May.

I just wonder why it was given to the Environment correspondent to write the piece . His specialty seems to be Climate change and disasters .

Such a ground breaking piece surely should have been given to a Health Correspondent . There's enough of them at the BBC . Hugh Pym , Fergus Walsh , Nick Triggle , Sophie Hutchinson , Catherine Burns, Laura Foster , Anna Collinson.

Maybe they were all busy that day ?

I'd rather not have an RNS on Friday mind you , unless the news is so good it just couldn't wait until Monday .

I think RM would see the poetic significance of a Manic Monday 2 .
A bit like Toy story 2 .

Well , shes on the up this morning .
I have a feeling our time is coming , and some sort of positive news is just around the corner .
We are touching distance away from P3 results ( in Pharma time terms )

Well I'm very happy with that update .
The best bits of Hav are getting bigger , and more HGZ found .
Sort of results any other gold explorer would give their right arm for .
If the SP stays put for a bit , fine with me , I'll just accumulate a bit more .
Enjoying watching this monster grow with every new report .

These reports always leave you wanting more. I wish they'd got the eastern zone assays back .

I'm looking forward to the experts on here breaking down the big significance of the latest drills :-)

For what its worth , two more sites recruiting on Activ2 ( Brazil and Argentina )
At least it shows the overall trial has been expanding .
Like others have noted , it doesn't mean we are available at all sites , but good to see more sites onboard .

Holding firm , and wishing a few of my other shares would take off a bit so I can add here at this level .

Oh , and then in May 21 they wrap up the patent issues for Traumakine in the USA .

Always lots going on in the background with Faron

Adding to that , Faron are still in a no win no fee arbitration process with Rentchler over them terminating the agreement ref manufacturing their active agent .

December 2019 - It came due to a need for a “significant” upgrade to the manufacturing process, required for approval from European and US authorities so that it can produce the drug.

Since then , Faron have set up AGC Biologics for commercial manufacture , and got a 2.5 million euro loan guarantee from Finnvera to set up the new manufacturing process .
This all bodes towards commercial production , for themselves , and potentially others ( eg Synairgen ) , particularly if the lyphyilised version is needed ( patent held by Faron ).

Reminds me of that George Best quote -"I spent a lot of money on booze, birds and fast cars. The rest I just squandered."

I think quite a few folk , me included , dropped a few more pennies into GGP after that tweet yesterday .

Lets hope we aren't picking through the bones of a 'Thunderbirdgate' inquiry tomorrow lol

Hello to you guys .
A few reasons keep me confident that we will find a successful route to market .
1.) There are many routes . Whether as a combi , or monotherapy , Bex seems to have potential in many areas . I see 4 possible P2 data sets giving reason to attract investment .
2.) Soluble Clever-1 - solving that problem makes Bex even more attractive .
3.) EIC , Business Finland , Cancer IO all on Farons side and bending over backwards to help them .
4.) IP around Bex has been growing , recently with the US patent for Bex granted.
5.)They have funding to see them through 2021 - which should give them time to finalise and announce P2 data .
6.) Traumakine is still there - robust IP progress again .
7.) Boston - now set up in the heart of the US city medical area to facilitate further business.
8.) New BOD member - USA based . Connections in US with DofD and also SAB .
9.) Commercial manufacture agreements in place for both lead therapies.
10.) BOD well placed to take care of business . Remember in 2018 they had a dress rehearsal .

Share price is at a healthy level . Sentiment is good .
Any further investment , from whatever direction , will not be at bargain basement price anymore .

Yesterdays webinar was a clear showcase for the connection with Hollmen labs and University of Turku .
Hosted on London Stock Exchange webinar service .
Why ? All information shown is readily available in RNS format .

Perhaps its aim was to lay the stall out so far , give credit to the research teams that have helped make the discovery , and bring them , and Maija also , more into the forefront , and give them some exposure .

Turku University Hospital will be involved in the Neo-adjuvant studies kicking off in Q4 2021 .

So perhaps Markku felt it was time to bring that side of the Faron team into the limelight .

Otherwise , I didn't see the need .
I'm sure there was a reason for it , that we are unaware of , as of now .

Giving Callum a big shout out now .
Infectious enthusiasm and pride in the project .